Journal
FUTURE MICROBIOLOGY
Volume 4, Issue 5, Pages 597-614Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.09.20
Keywords
antitubercular agent; drug development; drug resistance mechanism; mycobacteria; tuberculosis
Categories
Funding
- EC-VI Framework [LSHP-CT-2005-018923]
Ask authors/readers for more resources
TB is still a global health problem. The selection and spread of multidrug-resistant and extensively drug-resistant Mycobocterium tuberculosis strains represents a threat for global TB control. The reappearance of TB has driven an increased interest in understanding the mechanisms of drug action and drug resistance, which could provide a significant contribution in the development of new antimicrobials. In this article, the authors describe the mode of action and the resistance mechanisms of the principal first- and second-line antitubercular agents, namely isoniazid, ethionamide, ethambutol, D-Cycloserine, rifamycins, fluoroquinolones, streptomycin, linezolid and pyrazinamide. A brief outline of the seven drugs in clinical development is reported, showing how the development of new TB drugs is still required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available